Stocklytics Platform
Asset logo for symbol NRBO
NeuroBo Pharmaceuticals
NRBO
62
$4.10arrow_drop_up0.49%$0.02
High Growth
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$3.32
Prev. Close$4.06
EPS0.3
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap19918360.00
PE Ratio13.60
LOWHIGH
Day Range3.32
4.20
52 Week Range2.88
6.75
Ratios
P/B Ratio1.06
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %10.72%
EBITDA Margin %-
ROE %-108.42%
EPS0.3

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$901.74
Perf. (24h)
arrow_drop_up1.30%$11.63
Market Cap$840.04B
Price$484.48
Perf. (24h)
arrow_drop_down1.12%-$5.50
Market Cap$451.00B
Price$146.95
Perf. (24h)
arrow_drop_down1.45%-$2.17
Market Cap$357.99B
Price$132.79
Perf. (24h)
arrow_drop_down0.12%-$0.16
Market Cap$331.08B

About NeuroBo Pharmaceuticals (NRBO)

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Hyung-Heon Kim
Headquarters
Boston
Employees
2
Exchange
NASDAQ
add NeuroBo Pharmaceuticals  to watchlist

Keep an eye on NeuroBo Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for NeuroBo Pharmaceuticals (NRBO)?

For NeuroBo Pharmaceuticals (NRBO), the 52-week high is $6.75, which is 64.63% from the current price. The 52-week low is $2.89, the current price is 41.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
What is NeuroBo Pharmaceuticals 's (NRBO) price per share?

The current price per share for NeuroBo Pharmaceuticals (NRBO) is $4.1. The stock has seen a price change of $0.02 recently, indicating a 0.49% change. This reflects the stock's recent market performance and investor sentiment.

help
Is NeuroBo Pharmaceuticals (NRBO) a growth stock?

NeuroBo Pharmaceuticals (NRBO) has shown an average price growth of 0.41% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NeuroBo Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is NeuroBo Pharmaceuticals (NRBO) stock price performance year to date (YTD)?

As of the latest data, NeuroBo Pharmaceuticals (NRBO) has a year-to-date price change of -0.29%. Over the past month, the stock has experienced a price change of -0.73%. Over the last three months, the change has been -6.5%. Over the past six months, the figure is 23.13%.

help
Is NeuroBo Pharmaceuticals (NRBO) a profitable company?

NeuroBo Pharmaceuticals (NRBO) has a net income of -$12.47M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$15.89M. Furthermore, the EBITDA is -$20.24M.

help
What is the market capitalization of NeuroBo Pharmaceuticals (NRBO)?

NeuroBo Pharmaceuticals (NRBO) has a market capitalization of $19.92M. The average daily trading volume is 51.73K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level